SENS 218

Drug Profile

SENS 218

Alternative Names: SENS-218

Latest Information Update: 06 Jan 2017

Price : $50

At a glance

  • Originator Sensorion
  • Class Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Ear disorders

Most Recent Events

  • 06 Jan 2016 The Medicines and Healthcare products Regulatory Agency approves clinical trial application for phase I trial in Ear disorders
  • 01 Jan 2016 Phase-I clinical trials in Ear disorders (In volunteers) in United Kingdom (Sublingual)
  • 25 Aug 2015 Clinical trials in Ear disorders in France before August 2015 (Sublingual) (Sensorion website, August 2015)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top